Here are the 10-K annual reports from Tvardi Therapeutics, Inc. (TVRD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TVRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVRD filings page.
Tvardi Therapeutics, Inc. files its Form 10-K describing a clinical-stage pipeline of oral STAT3 inhibitors aimed at inflammatory and proliferative diseases. The company’s lead drug, TTI-101, is in a Phase 1b/2 REVERT LIVER CANCER trial for hepatocellular carcinoma, while TTI-109, a phosphate prodrug of TTI-101, is in a Phase 1 study in healthy volunteers with topline data expected in the second quarter of 2026.
The report explains how a 2025 merger with Cara Therapeutics created the current Tvardi entity, summarizes mixed IPF Phase 2 results that nonetheless showed biomarker and fibrosis improvements consistent with preclinical models, and details extensive global patent coverage and Baylor College of Medicine license agreements supporting long-lived intellectual property around TTI-101 and TTI-109.